Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claims 1-2, 8, 11, 14, 20, 27-28, 30, 35-36, 39, 42-43, 49, 53, 58 and 60-63 are presented for examination. Claim 1 is the sole independent claim.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1-2, 8, 11, 14, 20, 27-28, 30, 35-36, 39, 42-43, 49, 53, 58 and 60-63 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
i) The metes and bounds of atherosclerosis related diseases, disorders and conditions are not known. Applicants need to specifically point out which diseases are intended to be treated because the skilled artisan cannot say for sure which disease, disorder or condition, which is somehow related to atherosclerosis, is treatable by the instant claims.
ii) In claim 1, third line, “a compound of Formula XI” is mentioned but the structural formula depicted is named “Formula I.” Appropriate correction is required.
iii) The phrase “optionally substituted” without saying which substituents are intended is indefinite. One skilled in the art cannot say which substituents are permitted and which ones are not.
iv) In claim 8, there is no definition of Formula IA as this has been deleted. Appropriate correction is required.
v) In the dependent claims phrase such as, “method of claim1 having Formula IA” is in improper form. Language, such as, “wherein the compound of Formula I is a compound of Formula IA” is suggested. See claims 8, 27, 35, 39 and 42.
vi) The claims are drawn to a new use of an old compound. However, medical treatment of atherosclerosis is done using statins (or other cholesterol drugs) to lower LDL, Aspirin (to prevent blood clots), blood pressure medication and other medications used to control conditions that raise the risk of atherosclerosis. Applicants need to point out what the intended treatment is directed to.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRUCK KIFLE whose telephone number is (571)272-0668. The examiner can normally be reached 8 AM - 6 PM, M-F.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey H. Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
October 23, 2026
/BRUCK KIFLE/Primary Examiner, Art Unit 1624